- Home
- VALU vs DMAC Comparison
VALU vs DMAC Comparison
Compare VALU & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALU
- DMAC
- Stock Information
- Founded
- VALU 1931
- DMAC 2000
- Country
- VALU United States
- DMAC United States
- Employees
- VALU N/A
- DMAC N/A
- Industry
- VALU Investment Managers
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- VALU Finance
- DMAC Health Care
- Exchange
- VALU Nasdaq
- DMAC Nasdaq
- Market Cap
- VALU 340.4M
- DMAC 321.5M
- IPO Year
- VALU N/A
- DMAC N/A
- Fundamental
- Price
- VALU $36.86
- DMAC $8.91
- Analyst Decision
- VALU
- DMAC Strong Buy
- Analyst Count
- VALU 0
- DMAC 4
- Target Price
- VALU N/A
- DMAC $15.50
- AVG Volume (30 Days)
- VALU 3.3K
- DMAC 477.0K
- Earning Date
- VALU 12-12-2025
- DMAC 11-12-2025
- Dividend Yield
- VALU 3.50%
- DMAC N/A
- EPS Growth
- VALU 6.17
- DMAC N/A
- EPS
- VALU 2.26
- DMAC N/A
- Revenue
- VALU $34,801,000.00
- DMAC N/A
- Revenue This Year
- VALU N/A
- DMAC N/A
- Revenue Next Year
- VALU N/A
- DMAC N/A
- P/E Ratio
- VALU $15.96
- DMAC N/A
- Revenue Growth
- VALU N/A
- DMAC N/A
- 52 Week Low
- VALU $32.94
- DMAC $3.19
- 52 Week High
- VALU $55.01
- DMAC $9.15
- Technical
- Relative Strength Index (RSI)
- VALU 50.03
- DMAC 73.52
- Support Level
- VALU $36.03
- DMAC $7.06
- Resistance Level
- VALU $36.80
- DMAC $6.47
- Average True Range (ATR)
- VALU 0.84
- DMAC 0.64
- MACD
- VALU 0.06
- DMAC 0.27
- Stochastic Oscillator
- VALU 51.54
- DMAC 94.92
About VALU Value Line Inc.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.